Open Access

Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis

  • Authors:
    • Ling Ding
    • Haipeng Guo
    • Chao Zhang
    • Huixin Jin
    • Xuyang Guo
    • Tong Li
  • View Affiliations

  • Published online on: October 9, 2023     https://doi.org/10.3892/etm.2023.12244
  • Article Number: 545
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present meta‑analysis investigated the clinical value of serum matrix metalloproteinase (MMP)‑9 levels in Coronavirus Disease 2019 (COVID‑19) patients. Studies assessing the outcomes of patients with COVID‑19 in correlation with the MMP‑9 levels were retrieved from PubMed, Web of Science, EMBASE, Cochrane, WANFANG, and CNKI. A meta‑analysis was performed to compare the serum MMP‑9 levels between different patient groups: Severe vs. non‑severe; acute respiratory distress syndrome (ARDS) vs. non‑ARDS; non‑survivors vs. survivors; neurologic syndrome vs. non‑neurologic syndrome; and obese diabetic vs. non‑obese diabetic. A total of 2,062 COVID‑19‑confirmed patients from 12 studies were included in this meta‑analysis. The serum MMP‑9 levels were significantly higher in patients with severe COVID‑19 than in those with non‑severe COVID‑19 [weighted mean difference (WMD) 246.61 (95% confidence interval (CI), 115.86‑377.36), P<0.001]. Patients with ARDS exhibited significantly higher MMP‑9 levels than those without ARDS [WMD 248.55 (95% CI, 63.84‑433.25), P<0.001]. The MMP‑9 levels in the non‑survivors did not significantly differ from those in the survivors [WMD 37.79 (95% CI, ‑18.08‑93.65), P=0.185]. Patients with comorbidities, including neurological syndromes, and obese diabetic patients had significantly higher MMP‑9 levels than those without comorbidities [WMD 170.73 (95% CI, 95.61‑245.85), P<0.001]. Serum MMP‑9 levels were associated with COVID‑19 severity and may serve as a therapeutic target for improving the prognosis of patients with COVID‑19.
View Figures
View References

Related Articles

Journal Cover

December-2023
Volume 26 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding L, Guo H, Zhang C, Jin H, Guo X and Li T: Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis. Exp Ther Med 26: 545, 2023.
APA
Ding, L., Guo, H., Zhang, C., Jin, H., Guo, X., & Li, T. (2023). Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis. Experimental and Therapeutic Medicine, 26, 545. https://doi.org/10.3892/etm.2023.12244
MLA
Ding, L., Guo, H., Zhang, C., Jin, H., Guo, X., Li, T."Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis". Experimental and Therapeutic Medicine 26.6 (2023): 545.
Chicago
Ding, L., Guo, H., Zhang, C., Jin, H., Guo, X., Li, T."Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis". Experimental and Therapeutic Medicine 26, no. 6 (2023): 545. https://doi.org/10.3892/etm.2023.12244